Analytical Data
-
Gene name
HLA-A*02:01&B2M&PRAME Monomer(ALYVDSLFFL)
- Application
-
Alternative Names
HLA-A*0201 & B2M & PRAME (ALYVDSLFFL)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&ALYVDSLFFL
-
Molecular Weight
40-43 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01/B2M/PRAME monomer (ALYVDSLFFL) recombinant protein has garnered significant attention in the field of immunotherapy and cancer research due to its potential as a novel target for T-cell recognition. HLA-A*02:01 is a predominant human leukocyte antigen (HLA) class I molecule that presents peptide antigens to CD8+ T cells, playing a crucial role in the immune response against tumors. PRAME (Preferentially Expressed Antigen in Melanoma) is a cancer/testis antigen that is overexpressed in various malignancies, including melanoma, making it an attractive target for immune-mediated therapies. The combination of HLA-A*02:01 with B2M (beta-2 microglobulin) forms a stable heterodimer that is essential for proper antigen presentation. The specific peptide sequence ALYVDSLFFL derived from PRAME has been demonstrated to elicit strong T-cell responses, which may be exploited for vaccine development and adoptive T-cell therapy. Understanding the structure and function of this recombinant protein not only enhances our knowledge of immune recognition mechanisms but also paves the way for designing therapeutic strategies aimed at harnessing the immune system to specifically target and eliminate cancer cells expressing PRAME. This research could ultimately contribute to the advancement of personalized cancer immunotherapies, improving treatment outcomes for patients with HLA-A*02:01 positive tumors.
